Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2049-2056

  Wang, Chang Yi ^a   Walfield, Alan M ^a  

^a United Biomedical Inc   (United States)

Author keywords

Active; Immunotherapy; Peptide; T help

Indexed keywords

ALUMINUM HYDROXIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBODY; ANTIGEN; CANCER VACCINE; EPITOPE; GLYCYLALANYLTYROSYLALANYLARGINYLCYSTEINYLPROLYLASPARAGINYLGLYCYLTHREONYL ARGINYLALANYLLEUCYLTHREONYLVALYLALANYLGLUTAMYLLEUCYLARGINYLGLYCYLASPARAGINYL ALANYLGLUTAMYLLEUCINE; GONADORELIN; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INVASIN; ISOLEUCYLSERYLISOLEUCYLSERYLGLUTAMYLISOLEUCYLLYSYLGLYCYLVALYLISOLEUCYL VALYLHISTIDYLLYSYLISOLEUCYLGLUTAMYLTHREONYLISOLEUCYLLEUCYLPHENYLALANINE; ISOLEUCYLSERYLISOLEUCYLTHREONYLGLUTAMYLISOLEUCYLLYSYLGLYCYLVALYLISOLEUCYL VALYLHISTIDYLARGINYLISOLEUCYLGLUTAMYLTHREONYLISOLEUCYLLEUCYLPHENYLALANINE; LEUCYLSERYLGLUTAMYLISOLEUCYLLYSYLGLYCYLVALYLISOLEUCYLVALYLHISTIDYLARGINYL LEUCYLGLUTAMYLGLYCYLVALINE; LYSYLLYSYLGLUTAMINYLTYROSYLISOLEUCYLLYSYLALANYLASPARAGINYLSERYLLYSYL PHENYLALANYLISOLEUCYLGLYCYLISOLEUCYLTHREONYLGLUTAMYLLEUCINE; LYSYLLYSYLLYSYLISOLEUCYLISOLEUCYLTHREONYLISOLEUCYLTHREONYLARGINYLISOLEUCYL ISOLEUCYLTHREONYLISOLEUCYLISOLEUCYLTHREONYLTHREONYLISOLEUCYLASPARTIC ACID; LYSYLLYSYLLYSYLISOLEUCYLSERYLISOLEUCYLTHREONYLGLUTAMYLISOLEUCYLLYSYLGLYCYL VALYLISOLEUCYLVALYLHISTIDYLARGINYLISOLEUCYLGLUTAMYLTHREONYLISOLEUCYLLEUCYL PHENYLALANINE; MONTANIDE; PHENYLALANYLPHENYLALANYLLEUCYLLEUCYLTHREONYLARGINYLISOLEUCYLLEUCYLTHREONYL ISOLEUCYLPROLYLGLUTAMINYLSERYLLEUCYLASPARTIC ACID; SYNTHETIC PEPTIDE; UBITH; UNCLASSIFIED DRUG; VACCINE; VETERINARY DRUG; WATER OIL CREAM;

ACTIVE IMMUNIZATION; ALLERGY; ANTIBODY RESPONSE; BIOTECHNOLOGY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL TRANSPORT; CHRONIC DISEASE; CONFERENCE PAPER; COVALENT BOND; DISEASE CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MANUFACTURE; FOOT AND MOUTH DISEASE; GROWTH; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; LIVESTOCK; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; STIMULATION; SWINE; VETERINARY MEDICINE; VIRION; VIRUS;

EID: 14844318008     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.007     Document Type: Conference Paper

References (17)

1. C.L. Finstad, C.Y. Wang, and J. Kowalski Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy Vaccine 22 2004 1300 1313
2. C.Y. Wang, A.M. Walfield, and X. Fang Synthetic IgE peptide vaccine for immunotherapy of allergy Vaccine 21 15 2003 1580 1590
3. C.Y. Wang, M. Shen, and G. Tam Synthetic AIDS vaccine by targeting HIV receptor Vaccine 21 1-2 2002 89 97
4. C.Y. Wang, T.Y. Chang, and A.M. Walfield Effective synthetic peptide vaccine for foot-and-mouth disease in swine Vaccine 20 19-20 2002 2603 2610
5. Sokoll KK. Stabilized synthetic immunogen delivery system. US Patent Application Publication No. 20040009897 UBI, USA;2004.
6. C.D. Partidos, C.M. Stanley, and M.W. Steward Immune responses in mice following immunization with chimeric synthetic peptides representing B and T cell epitopes of measles virus proteins J Gen Virol 72 1991 1293 1299
7. Wang CY. Artificial T helper epitopes as immune stimulators for synthetic peptide immunogens. US Patent No. 6,713,301 B1 United Biomedical Inc., USA; 2004.
8. G.P. Talwar Vaccines for control of fertility and hormone-dependent cancers Immunol Cell Biol 75 1997 184 189
9. M.S. Simm, D.P. Scholfield, and E. Jacobs Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer Br J Cancer 83 2000 443 446
10. C.Y. Wang, L.S.W. Sawyer, and K.K. Murthy Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex Proc Natl Acad Sci USA 96 1999 10367 10372
11. D.R. Kuritzkes, J. Jacobson, and W.G. Powderly Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1 J Infect Dis 189 2004 286 291
12. H. Milgrom, R.B.J. Fick, and J.Q. Su Treatment of allergic asthma with monoclonal anti-IgE antibody N Engl J Med 341 1966-1973
13. B. Hammerberg, D. Bevier, and D.J. DeBoer Auto IgG anti-IgE and IgG X IgE immune complex presence and effects on ELISA-based quantitation of IgE in canine atopic dermatitis, demodectic acariasis and helminthiasis Vet Immunol Immunopathol 60 1997 33 46
14. F. Brown New Approaches to Vaccination Against Foot-and-Mouth Disease Vaccine 10 14 1992 1022 1026
15. O.I.E. chapter 2.1.1 foot and mouth disease. Manual Of Standards For Diagnostic Tests And Vaccines Office International des Epizooties, Paris, France;1996. p. 47-56.
16. F. Shen, P.D. Chen, and A.M. Walfield Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA Vaccine 17 1999 3039 3049
17. Wang CY. Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease. United States Patent Application Publication US2003/0068325 A1 United Biomedical, Inc., US;2003.